NDAORALFOR SUSPENSION
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VARIBAR THIN LIQUID (barium sulfate) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARIBAR THIN LIQUID is an oral barium sulfate suspension used as a radiographic contrast agent for X-ray imaging procedures. It enables visualization of the gastrointestinal tract during diagnostic radiography. The product works by attenuating X-rays to create contrast between anatomical structures.
Peak
Product is in peak lifecycle stage within Bracco's contrast agent portfolio, suggesting stable commercial operations with mature team structures.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Career Relevance
VARIBAR THIN LIQUID is a mature diagnostic imaging product with stable, predictable revenue but limited growth opportunities. Careers on this brand emphasize market maintenance, healthcare provider relationships, and optimization of existing product utilization rather than innovation or expansion.
Worked on VARIBAR THIN LIQUID at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.